Mapping the Genomic Landscape to Accelerate Precision Drug Development

Join Alastair Garfield, PhD, Executive Director of R&D and Translation Medicine at Rhythm Pharmaceuticals and Dr. Mark Kiel, Founder and Chief Science Officer at Genomenon, as they share how a database of genes and variants associated with obesity was developed in less than 60 days, including scientific evidence complete with literature citations and ACMG interpretations for each mutation. The machine-learning driven process replaced several years of manual research of the scientific literature to find obesity-related mutations.